Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,615.60
(
0.23%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
102.58
(
0.46%
)
Bitcoin
76,689.93
(
-0.88%
)
News Focus
News Focus
Post# of 257454
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205459

Saturday, 11/19/2016 11:25:19 AM

Saturday, November 19, 2016 11:25:19 AM

Post# of 257454
EXAS—CEO/COO/CSO sold cumulative $28M of stock during the past week or so:

https://www.sec.gov/Archives/edgar/data/1124140/000120919116150334/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150333/xslF345X03/doc4.xml
https://www.sec.gov/Archives/edgar/data/1124140/000120919116150335/xslF345X03/doc4.xml

Cologuard is a fine product, but selling a diagnostic for colorectal cancer is a tough way to make money.

EXAS lost $38M in 3Q16 and $130M during 2016’s first nine months. Cologuard was approved by the FDA more than two years ago (#msg-105198793).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today